We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias
Cancer Treat. Rev 2022 Nov 01;110(xx)102452, M Kfoury, M Najean, A Lappara, AL Voisin, S Champiat, JM Michot, S Laghouati, C Robert, B Besse, JC Soria, O Lambotte, C Massard, A Marabelle, M Texier